The monetary value of a reduction in mortality risk is often quantified using one of three concepts: the “value per statistical life” (VSL),“value per statistical life year” (VSLY),
Read more...Including Spillover Effects in Economic Evaluation
Edward Henry, doctoral student at the University of Galway, presented a set of new recommendations for incorporating “health spillover” into the economic evaluations
Read more...CHDS at 2023 Benefit-Cost Conference
The Society for Benefit-Cost Analysis 2023 annual conference featured work conducted by several CHDS researchers. Faculty member James Hammitt presented his work
Read more...Preventing Coronary Heart Disease from Diabetes
People living with type 2 diabetes have a higher risk of coronary heart disease (CHD). In a CHDS seminar, Bart Ferket discussed using risk stratification to prevent CHD among diabetics.
Read more...Jameson Receives Raiffa Award
Jacob Jameson, first-year student in the Harvard PhD Program in Health Policy, has received the 2022 Howard Raiffa Fund award. The Howard Raiffa Fund was established in 1996
Read more...Jennifer Yeh Promoted to Associate Professor
Jennifer Yeh, CHDS affiliate and scientific researcher at Boston Children’s Hospital, has been promoted to Associate Professor of Pediatrics at the Harvard Medical School.
Read more...CHDS Welcomes New Doctoral Students
CHDS welcomes Jenna Rogers and Jacob Jameson, new students in the PhD Program in Health Policy decision science track, beginning Fall 2022. Jenna Rogers graduated from
Read more...Relative Health Improvements with Alternative Frameworks
The social value of decreasing health risks to people of different age, health status, and income depends on the evaluation framework employed in an analysis. These values can be evaluated using cost-effectiveness
Read more...Post-Acute Care in China
Fangli Geng, Ph.D. candidate at CHDS, collaborated with researchers from the Chinese Academy of Medical Sciences & Peking Union Medical College to develop
Read more...Cost-Ineffectiveness of Lockdowns
COVID-19 vaccination is substantially more cost-effective than lockdowns, according to research conducted by CHDS faculty affiliate Joseph Pliskin and Ronen Arbel. Early in the COVID-19
Read more...